Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ulrika Nillroth"'
Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs
Autor:
Per-Olof Markgren, Ulrika Nillroth, Anders Hallberg, Johan Hultén, Lotta Vrang, U H Danielson
Publikováno v:
Antimicrobial Agents and Chemotherapy. 41:2383-2388
Resistant virus was isolated from virus propagated in cell culture in the presence of the human immunodeficiency virus type 1 (HIV-1) proteinase inhibitor DMP 323, Ro 31-8959, or A-75925. The proteinase gene of resistant virus was sequenced, and key
Autor:
Anders Hallberg, Bertil Samuelsson, U. Helena Danielson, Ingemar Kvarnström, Anders Karlén, Ulrika Nillroth, Daniel Nöteberg, Jonas Brånalt, Björn Classon
Publikováno v:
Tetrahedron. 53:7975-7984
The synthesis of the four diastereomeric 2-aminocyclopentanecarboxylic acids, their use as replacements for proline in potential HIV protease inhibitors containing a hydroxyethylamine dipeptide isostere and the evaluation of the biological activity o
Autor:
Jonas Brånalt, Ingemar Kvarnström, Anders Karlén, Anders Hallberg, Ulrika Nillroth, Bertil Samuelsson, U. Helena Danielson, Björn Classon
Publikováno v:
Tetrahedron Letters. 38:3483-3486
A convenient synthesis of 1-(S)-[1'-(S)-(t-butyloxycarbonylamino)-2'-phenylethyl]oxirane : a useful building block in the synthesis of HIV protease inhibitors
Autor:
Goran Ahlsen, Neeraj Garg, Björn Classon, Seved Löwgren, Torsten Unge, Anna Mühlman, Anders Karlén, H.O. Andersson, U.H. Danielsson, Anders Hallberg, Bertil Samuelsson, Wesley Schaal, Magnus Björsne, Ulrika Nillroth, Ingemar Kvarnström, Mathias Alterman, K. Fridborg, B. Oberg, Lotta Vrang
Publikováno v:
European journal of biochemistry. 270(8)
HIV-1 protease is an important target for treatment of AIDS, and efficient drugs have been developed. However, the resistance and negative side effects of the current drugs has necessitated the development of new compounds with different binding patt
Publikováno v:
Aspartic Proteinases ISBN: 9781461374527
Development of drugs against HIV is dependent on a detailed understanding of the enzymatic properties of the target viral enzymes and how different ligands can interfere with their catalytic properties. The viral proteinase is responsible for process
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c32cdd254617c7824dd181840995e9d1
https://doi.org/10.1007/978-1-4615-5373-1_13
https://doi.org/10.1007/978-1-4615-5373-1_13
Autor:
Lars Hagberg, Aylin Yilmaz, Magnus Gisslén, Lars Ståhle, Jan-Olof Svensson, Ulrika Nillroth, Dietmar Fuchs
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 6, Iss 1, p 63 (2006)
BMC Infectious Diseases, Vol 6, Iss 1, p 63 (2006)
Background The way various antiretroviral drugs and drug combinations affect HIV-1 infection in the central nervous system is still largely unknown. The aim of this study was to determine the cerebrospinal fluid (CSF) steady-state concentrations of s